Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies

被引:65
作者
Podhorna, Jana [1 ]
Krahnke, Tillmann [2 ]
Shear, Michael [3 ]
Harrison, John E. [4 ]
机构
[1] Boehringer Ingelheim Pharma GmbH & Co KG, Binger Str 173, D-55218 Ingelheim, Germany
[2] Cogitars GmbH, Heidelberg, Germany
[3] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
[4] Vrije Univ Amsterdam, Med Ctr Amsterdam, Amsterdam, Netherlands
来源
ALZHEIMERS RESEARCH & THERAPY | 2016年 / 8卷
基金
加拿大健康研究院;
关键词
ADAS-Cog; Enrichment markers; Mild Alzheimer's disease; Mild cognitive impairment; t-Tau/A beta ratio; Decline over time; MENTAL-STATE-EXAMINATION; CLINICAL-TRIALS; CRITERIA; DECLINE;
D O I
10.1186/s13195-016-0170-5
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Development of new treatments for Alzheimer's disease (AD) has broadened into early interventions in individuals with modest cognitive impairment and a slow decline. The 11-item version of the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) was originally developed to measure cognition in patients with mild to moderate AD. Attempts to improve its properties for early AD by removing items prone to ceiling and/or by adding cognitive measures known to be impaired early have yielded a number of ADAS-Cog variants. Using Alzheimer's Disease Neuroimaging Initiative data, we compared the performance of the 3-, 5-, 11- and 13-item ADAS-Cog variants in subjects with early AD. Given the interest in enrichment strategies, we also examined this aspect with a focus on cerebrospinal fluid (CSF) markers. Methods: Subjects with mild cognitive impairment (MCI) and mild AD with available ADAS-Cog 13 and CSF data were analysed. The decline over time was defined by change from baseline. Direct cross-comparison of the ADAS-Cog variants was performed using the signal-to-noise ratio (SNR), with higher values reflecting increased sensitivity to detect change over time. Results: The decline over time on any of the ADAS-Cog variants was minimal in subjects with MCI. Approximately half of subjects with MCI fulfilled enrichment criteria for positive AD pathology. The impact of enrichment was detectable but subtle in MCI. The annual decline in mild AD was more pronounced but still modest. More than 90 % of subjects with mild AD had positive AD pathology. SNRs were low in MCI but greater in mild AD. The numerically largest SNRs were seen for the ADAS-Cog 5 in MCI and for both the 5- and 13-item ADAS-Cog variants in mild AD, although associated confidence intervals were large. Conclusions: The possible value of ADAS-Cog expansion or reduction is less than compelling, particularly in MCI. In mild AD, adding items known to be impaired at early stages seems to provide more benefit than removing items on which subjects score close to ceiling.
引用
收藏
页数:13
相关论文
共 39 条
  • [1] Cognitive Changes Preceding Clinical Symptom Onset of Mild Cognitive Impairment and Relationship to ApoE Genotype
    Albert, Marilyn
    Soldan, Anja
    Gottesman, Rebecca
    McKhann, Guy
    Sacktor, Ned
    Farrington, Leonie
    Grega, Maura
    Turner, Raymond
    Lu, Yi
    Li, Shanshan
    Wang, Mei-Cheng
    Selnes, Ola
    [J]. CURRENT ALZHEIMER RESEARCH, 2014, 11 (08) : 773 - 784
  • [2] Alzheimer's disease
    Scheltens, Philip
    De Strooper, Bart
    Kivipelto, Miia
    Holstege, Henne
    Chetelat, Gael
    Teunissen, Charlotte E.
    Cummings, Jeffrey
    van der Flier, Wiesje M.
    [J]. LANCET, 2021, 397 (10284) : 1577 - 1590
  • [3] Fluid Biomarkers in Alzheimer Disease
    Blennow, Kaj
    Zetterberg, Henrik
    Fagan, Anne M.
    [J]. COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2012, 2 (09):
  • [4] APOE-4 Genotype and Neurophysiological Vulnerability to Alzheimer's and Cognitive Aging
    Bookheimer, Susan
    Burggren, Alison
    [J]. ANNUAL REVIEW OF CLINICAL PSYCHOLOGY, 2009, 5 : 343 - 362
  • [5] Cozby P.C., 2009, Methods in Behavioral Research, V10th
  • [6] The relative efficiency of time-to-threshold and rate of change in longitudinal data
    Donohue, M. C.
    Gamst, A. C.
    Thomas, R. G.
    Xu, R.
    Beckett, L.
    Petersen, R. C.
    Weiner, M. W.
    Aisen, P.
    [J]. CONTEMPORARY CLINICAL TRIALS, 2011, 32 (05) : 685 - 693
  • [7] The Alzheimer's disease assessment scale: Evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimer's disease
    Doraiswamy, PM
    Kaiser, L
    Bieber, F
    Garman, RL
    [J]. ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2001, 15 (04) : 174 - 183
  • [8] Research criteria for the diagnosis of Alzheimer"s disease: revising the NINCDS-ADRDA criteria
    Dubois, Bruno
    Feldman, Howard H.
    Jacova, Claudia
    Dekosky, Steven T.
    Barberger-Gateau, Pascale
    Cummings, Jeffrey
    Delocourte, Andre
    Galasko, Douglas
    Gauthier, Serge
    Jicha, Gregory
    Meguro, Kenichi
    O'Brien, John
    Pasquier, Florence
    Robert, Philippe
    Rossor, Martin
    Solloway, Steven
    Stern, Yaakov
    Visser, Pieter J.
    Scheltens, Philip
    [J]. LANCET NEUROLOGY, 2007, 6 (08) : 734 - 746
  • [9] Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
    Dubois, Bruno
    Feldman, Howard H.
    Jacova, Claudia
    Hampel, Harald
    Molinuevo, Jose Luis
    Blennow, Kaj
    Dekosky, Steven T.
    Gauthier, Serge
    Selkoe, Dennis
    Bateman, Randall
    Cappa, Stefano
    Crutch, Sebastian
    Engelborghs, Sebastiaan
    Frisoni, Giovanni B.
    Fox, Nick C.
    Galasko, Douglas
    Habert, Marie-Odile
    Jicha, Gregory A.
    Nordberg, Agneta
    Pasquier, Florence
    Rabinovici, Gil
    Robert, Philippe
    Rowe, Christopher
    Salloway, Stephen
    Sarazin, Marie
    Epelbaum, Stephane
    de Souza, Leonardo C.
    Vellas, Bruno
    Visser, Pieter J.
    Schneider, Lon
    Stern, Yaakov
    Scheltens, Philip
    Cummings, Jeffrey L.
    [J]. LANCET NEUROLOGY, 2014, 13 (06) : 614 - 629
  • [10] Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative
    Grill, Joshua D.
    Di, Lijie
    Lu, Po H.
    Lee, Cathy
    Ringman, John
    Apostolova, Liana G.
    Chow, Nicole
    Kohannim, Omid
    Cummings, Jeffrey L.
    Thompson, Paul M.
    Elashoff, David
    [J]. NEUROBIOLOGY OF AGING, 2013, 34 (01) : 62 - 72